By Professor Jason Grebely

Journal articles

Dalgard O; Litwin AH; Shibolet O; Grebely J; Nahass R; Altice FL; Conway B; Gane EJ; Luetkemeyer AF; Peng CY; Iser D; Gendrano IN; Kelly MM; Haber BA; Platt H; Puenpatom A, 2023, 'Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection', Journal of Addictive Diseases, 41, pp. 213 - 224, http://dx.doi.org/10.1080/10550887.2022.2088978

Casey JL; Dore GJ; Grebely J; Matthews GV; Cherepanov V; Martinello M; Marks P; Janssen HLA; Hansen BE; Kaul R; MacParland SA; Gehring AJ; Feld JJ, 2023, 'Hepatitis C virus-specific immune responses following direct-acting antivirals administered during recent hepatitis C virus infection', Journal of Viral Hepatitis, 30, pp. 64 - 72, http://dx.doi.org/10.1111/jvh.13761

Cunningham EB; Wheeler A; Hajarizadeh B; French CE; Roche R; Marshall AD; Fontaine G; Conway A; Bajis S; Valencia BM; Presseau J; Ward JW; Degenhardt L; Dore GJ; Hickman M; Vickerman P; Grebely J, 2023, 'Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis', International Journal of Drug Policy, 111, http://dx.doi.org/10.1016/j.drugpo.2022.103917

Conway A; Treloar C; Crawford S; Grebely J; Marshall AD, 2023, 'People engaged in opioid agonist treatment as a counterpublic during the COVID-19 pandemic in Australia: A qualitative study', Drug and Alcohol Review, 42, pp. 203 - 212, http://dx.doi.org/10.1111/dar.13531

Grebely J; Robaeys G; Bruggmann P; Aghemo A; Backmund M; Bruneau J; Byrne J; Dalgard O; Feld JJ; Hellard M; Hickman M; Kautz A; Litwin A; Lloyd AR; Mauss S; Prins M; Swan T; Schaefer M; Taylor LE; Dore GJ, 2023, 'Recomendaciones para el manejo de la infección por el virus de la hepatitis C entre usuarios de drogas por vía parenteral', International Journal of Drug Policy, 111, http://dx.doi.org/10.1016/j.drugpo.2015.11.011

Grebely J; Robaeys G; Bruggmann P; Aghemo A; Backmund M; Bruneau J; Byrne J; Dalgard O; Feld JJ; Hellard M; Hickman M; Kautz A; Litwin A; Lloyd AR; Mauss S; Prins M; Swan T; Schaefer M; Taylor LE; Dore GJ, 2023, 'Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection', International Journal of Drug Policy, 111, pp. 101669, http://dx.doi.org/10.1016/j.drugpo.2015.11.009

Matthews SJ; Shephard MD; Grebely J; Guy RJ, 2023, 'Decentralised point-of-care testing for acute, chronic and infectious disease – benefits and challenges', Pathology, 55, pp. S7 - S7, http://dx.doi.org/10.1016/j.pathol.2022.12.029

Valerio H; Conway A; Alavi M; Treloar C; Silk D; Murray C; Henderson C; Amin J; Read P; Degenhardt L; Christmass M; Montebello M; Dore GJ; Grebely J, 2022, 'Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study', International Journal of Drug Policy, 110, http://dx.doi.org/10.1016/j.drugpo.2022.103876

Carson JM; Dore GJ; Lloyd AR; Grebely J; Byrne M; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Matthews GV; Hajarizadeh B, 2022, 'Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study', Clinical Infectious Diseases, 75, pp. 1809 - 1819, http://dx.doi.org/10.1093/cid/ciac246

Conway A; Read P; Gilliver R; McNaughton T; Valerio H; Cunningham EB; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Grebely J, 2022, 'Awareness of HCV Status and Preferences for Testing and Treatment among People with Recent Injecting Drug Use at a Peer-Led Needle and Syringe Program: The TEMPO Pilot Study', Viruses, 14, http://dx.doi.org/10.3390/v14112463

Catlett B; Hajarizadeh B; Cunningham E; Wolfson-Stofko B; Wheeler A; Khandaker-Hussain B; Feld JJ; Martró E; Chevaliez S; Pawlotsky JM; Bharat C; Cunningham PH; Dore GJ; Applegate T; Grebely J, 2022, 'Diagnostic Accuracy of Assays Using Point-of-Care Testing or Dried Blood Spot Samples for the Determination of Hepatitis C Virus RNA: A Systematic Review', Journal of Infectious Diseases, 226, pp. 1005 - 1021, http://dx.doi.org/10.1093/infdis/jiac049

Grebely J; Dore GJ; Altice FL; Conway B; Litwin AH; Norton BL; Dalgard O; Gane EJ; Shibolet O; Nahass R; Luetkemeyer AF; Peng CY; Iser D; Gendrano IN; Kelly MM; Hwang P; Asante-Appiah E; Haber BA; Barr E; Robertson MN; Platt H, 2022, 'Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy A Cohort Study', Annals of Internal Medicine, 175, pp. 1221 - 1229, http://dx.doi.org/10.7326/M21-4119

Lafferty L; Rance J; Byrne M; Milat A; Dore GJ; Grebely J; Lloyd AR; Treloar C, 2022, '“You need a designated officer” – Recommendations from correctional and justice health personnel for scaling up hepatitis C treatment-as-prevention in the prison setting', International Journal of Drug Policy, 106, http://dx.doi.org/10.1016/j.drugpo.2022.103746

Wheeler A; Valerio H; Cunningham EB; Martinello M; Barocas JA; Colledge-Frisby S; Treloar C; Amin J; Henderson C; Read P; Matthews GV; Dunlop AJ; Gorton C; Hayllar J; Alavi M; Murray C; Marks P; Silk D; Degenhardt L; Dore GJ; Grebely J, 2022, 'Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage Study', Drug and Alcohol Dependence, 237, http://dx.doi.org/10.1016/j.drugalcdep.2022.109543

Conway A; Valerio H; Alavi M; Silk D; Treloar C; Hajarizadeh B; Marshall AD; Martinello M; Milat A; Dunlop A; Murray C; Prain B; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Christmass M; Wade A; Montebello M; Dore GJ; Grebely J, 2022, 'A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study', Viruses, 14, http://dx.doi.org/10.3390/v14071555

Yousafzai MT; Alavi M; Valerio H; Hajarizadeh B; Grebely J; Dore GJ, 2022, 'Timely Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy among People with Hepatitis C in New South Wales, Australia', Viruses, 14, pp. 1496, http://dx.doi.org/10.3390/v14071496

Marshall AD; Conway A; Cunningham EB; Valerio H; Silk D; Alavi M; Wade A; Lam T; Zohrab K; Dunlop A; Connelly C; Christmass M; Cock V; Burns C; Henderson C; Wiseman V; Dore GJ; Grebely J, 2022, 'Willingness of people who inject drugs to participate in a randomised controlled trial involving financial incentives to initiate hepatitis C treatment', Drug and Alcohol Dependence, 235, http://dx.doi.org/10.1016/j.drugalcdep.2022.109438

Lazarus JV; Picchio CA; Byrne CJ; Crespo J; Colombo M; Cooke GS; Dore GJ; Grebely J; Ward JW; Dillon JF, 2022, 'A Global Systematic Review of Hepatitis C Elimination Efforts through Micro-Elimination', Seminars in Liver Disease, 42, pp. 159 - 172, http://dx.doi.org/10.1055/a-1777-6112

Howe AYM; Rodrigo C; Cunningham EB; Douglas MW; Dietz J; Grebely J; Popping S; Sfalcin JA; Parczewski M; Sarrazin C; de Salazar A; Fuentes A; Sayan M; Quer J; Kjellin M; Kileng H; Mor O; Lennerstrand J; Fourati S; Di Maio VC; Chulanov V; Pawlotsky JM; Harrigan PR; Ceccherini-Silberstein F; Garcia F; Martinello M; Matthews G; Fernando FF; Esteban JI; Müllhaupt B; Wiesch JSZ; Buggisch P; Neumann-Haefelin C; Berg T; Berg CP; Schattenberg JM; Moreno C; Stauber R; Lloyd A; Dore G; Applegate T; Ignacio J; Garcia-Cehic D; Gregori J; Rodriguez-Frias F; Rando A; Gozlan Y; Angelico M; Andreoni M; Babudieri S; Bertoli A; Cento V; Coppola N; Craxì A; Paolucci S; Parruti G; Pasquazzi C; Perno CF; Teti E; Vironet C; Lannergård A; Duberg AS; Aleman S; Gutteberg T; Soulier A; Gourgeon A; Chevaliez S; Pol S; Carrat F; Salmon D; Kaiser R; Knopes E; Gomes P; de Kneght R; Rijnders B; Poljak M; Lunar M; Usubillaga R; Seguin_Devaux C; Tay E; Wilson C; Wang DS; George J; Kok J; Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A, 2022, 'Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals', JHEP Reports, 4, pp. 100462, http://dx.doi.org/10.1016/j.jhepr.2022.100462

Blach S; Terrault NA; Tacke F; Gamkrelidze I; Craxi A; Tanaka J; Waked I; Dore GJ; Abbas Z; Abdallah AR; Abdulla M; Aghemo A; Aho I; Akarca US; Alalwan AM; Alanko Blomé M; Al-Busafi SA; Aleman S; Alghamdi AS; Al-Hamoudi WK; Aljumah AA; Al-Naamani K; Al Serkal YM; Altraif IH; Anand AC; Anderson M; Andersson MI; Athanasakis K; Baatarkhuu O; Bakieva SR; Ben-Ari Z; Bessone F; Biondi MJ; Bizri ARN; Brandão-Mello CE; Brigida K; Brown KA; Brown, RS; Bruggmann P; Brunetto MR; Busschots D; Buti M; Butsashvili M; Cabezas J; Chae C; Chaloska Ivanova V; Chan HLY; Cheinquer H; Cheng KJ; Cheon ME; Chien CH; Chien RN; Choudhuri G; Christensen PB; Chuang WL; Chulanov V; Cisneros LE; Coco B; Contreras FA; Cornberg M; Cramp ME; Crespo J; Cui F; Cunningham CW; Dagher Abou L; Dalgard O; Dao DY; De Ledinghen V; Derbala MF; Deuba K; Dhindsa K; Djauzi S; Drazilova S; Duberg AS; Elbadri M; El-Sayed MH; Esmat G; Estes C; Ezzat S; Färkkilä MA; Ferradini L; Ferraz MLG; Ferreira PRA; Filipec Kanizaj T; Flisiak R; Frankova S; Fung J; Gamkrelidze A; Gane E; Garcia V; García-Samaniego J; Gemilyan M; Genov J; Gheorghe LS; Gholam PM; Goldis A; Gottfredsson M; Gray RT; Grebely J; Gschwantler M, 2022, 'Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study', The Lancet Gastroenterology and Hepatology, 7, pp. 396 - 415, http://dx.doi.org/10.1016/S2468-1253(21)00472-6

Cunningham EB; Wheeler A; Hajarizadeh B; French CE; Roche R; Marshall AD; Fontaine G; Conway A; Valencia BM; Bajis S; Presseau J; Ward JW; Degenhardt L; Dore GJ; Hickman M; Vickerman P; Grebely J, 2022, 'Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis', The Lancet Gastroenterology and Hepatology, 7, pp. 426 - 445, http://dx.doi.org/10.1016/S2468-1253(21)00471-4

Marshall AD; Rance J; Grebely J; Treloar C, 2022, '‘Not just one box that you tick off’ – Deconstructing the hepatitis C care cascade in the interferon-free direct acting antiviral era from the client perspective', International Journal of Drug Policy, 102, http://dx.doi.org/10.1016/j.drugpo.2022.103610

Farrell M; Shahbazi J; Byrne M; Grebely J; Lintzeris N; Chambers M; Larance B; Ali R; Nielsen S; Dunlop A; Dore GJ; McDonough M; Montebello M; Nicholas T; Weiss R; Rodgers C; Cook J; Degenhardt L, 2022, 'Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence', International Journal of Drug Policy, 100, http://dx.doi.org/10.1016/j.drugpo.2021.103492

Lafferty L; Cochrane A; Sheehan Y; Treloar C; Grebely J; Lloyd AR, 2022, '“That was quick, simple, and easy”: Patient perceptions of acceptability of point-of-care hepatitis C RNA testing at a reception prison', International Journal of Drug Policy, 99, http://dx.doi.org/10.1016/j.drugpo.2021.103456

Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J; ETHOS Engage Study Group , 2022, 'Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.', Int J Drug Policy, 105, pp. 103706, http://dx.doi.org/10.1016/j.drugpo.2022.103706

Rance J; Lafferty L; Treloar C; Loveday S; Dore G; Lloyd A; Grebely J; Butler T; Martin N; Chambers G; Byrne M; Donnelly R; McGrath C; Bowman J; Trevethan L; Grant L; Murrell T; Bath N; Harrod M; Churchill A; Pinnock K; Cairnduff S, 2021, 'Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian ‘surveillance and treatment of prisoners with hepatitis C’ project (SToP-C)', Harm Reduction Journal, 18, pp. 46, http://dx.doi.org/10.1186/s12954-021-00494-4

Lafferty L; Rance J; Dore GJ; Grebely J; Lloyd AR; Treloar C, 2021, 'Hepatitis C treatment as prevention in the prison setting: Assessments of acceptability of treatment scale up efforts by prison correctional and health personnel', International Journal of Drug Policy, 98, http://dx.doi.org/10.1016/j.drugpo.2021.103379

Valerio H; Alavi M; Law M; McManus H; Tillakeratne S; Bajis S; Martinello M; Matthews GV; Amin J; Janjua NZ; Krajden M; George J; Degenhardt L; Grebely J; Dore GJ, 2021, 'Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study', Clinical Infectious Diseases, 73, pp. 2037 - 2044, http://dx.doi.org/10.1093/cid/ciab526

Gibbs D; Grebely J; Sutherland R; Larney S; Butler K; Dietze PM; Starr M; Peacock A, 2021, 'Concordance between self-reported and current hepatitis C virus infection status in a sample of people who inject drugs in Sydney and Canberra, Australia', Drug and Alcohol Review, 40, pp. 1349 - 1353, http://dx.doi.org/10.1111/dar.13282

Lim AG; Stone J; Hajarizadeh B; Byrne M; Chambers GM; Martin NK; Grebely J; Dore GJ; Lloyd AR; Vickerman P, 2021, 'Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons', Hepatology, 74, pp. 2366 - 2379, http://dx.doi.org/10.1002/hep.32002

Gibbs D; Price O; Grebely J; Larney S; Sutherland R; Read P; Butler K; Degenhardt L; Peacock A, 2021, 'Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system', Drug and Alcohol Dependence, 228, http://dx.doi.org/10.1016/j.drugalcdep.2021.109050

Stafford F; Dore GJ; Clackett S; Martinello M; Matthews GV; Grebely J; Balcomb AC; Hajarizadeh B, 2021, 'Prescribing of direct-acting antiviral therapy by general practitioners for people with hepatitis C in an unrestricted treatment program', Medical Journal of Australia, 215, pp. 332 - 333, http://dx.doi.org/10.5694/mja2.51204

Artenie AA; Hickman M; Vickerman P; Stone J; Grebely J; Bruneau J, 2021, 'Diversity of incarceration patterns among people who inject drugs and the association with incident hepatitis C virus infection', International Journal of Drug Policy, 96, http://dx.doi.org/10.1016/j.drugpo.2021.103419

Rance J; Lafferty L; Treloar C; Loveday S; Dore G; Lloyd A; Grebely J; Butler T; Martin N; Chambers G; Byrne M; Donnelly R; McGrath C; Bowman J; Trevethan L; Grant L; Murrell T; Bath N; Harrod M; Churchill A; Pinnock K; Cairnduff S, 2021, 'Expert stakeholder perspectives on the acceptability of treatment-as-prevention in prison: a qualitative substudy of the ‘Surveillance and Treatment of Prisoners with Hepatitis C’ project (SToP-C)', Addiction, 116, pp. 2761 - 2769, http://dx.doi.org/10.1111/add.15477

Yousafzai MT; Bajis S; Alavi M; Grebely J; Dore GJ; Hajarizadeh B, 2021, 'Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta-analysis', Journal of Viral Hepatitis, 28, pp. 1340 - 1354, http://dx.doi.org/10.1111/jvh.13574

Fortier E; Høj SB; Sylvestre MP; Artenie AA; Minoyan N; Jutras-Aswad D; Grebely J; Bruneau J, 2021, 'Injecting frequency trajectories and hepatitis C virus acquisition: Findings from a cohort of people who inject drugs in Montréal, Canada', International Journal of Drug Policy, 96, http://dx.doi.org/10.1016/j.drugpo.2021.103439

Conway A; Valerio H; Peacock A; Degenhardt L; Hayllar J; Harrod ME; Henderson C; Read P; Gilliver R; Christmass M; Dunlop A; Montebello M; Whitton G; Reid D; Lam T; Alavi M; Silk D; Marshall AD; Treloar C; Dore GJ; Grebely J, 2021, 'Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study', International Journal of Drug Policy, 96, http://dx.doi.org/10.1016/j.drugpo.2021.103421

Grebely J; Collins AB; Artenie AA; Sutherland R; Meyer JP; Barocas JA; Falade-Nwulia O; Cepeda JA; Cunningham EB; Hajarizadeh B; Lafferty L; Lazarus JV; Bonn M; Marshall AD; Treloar C, 2021, 'Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs', International Journal of Drug Policy, 96, http://dx.doi.org/10.1016/j.drugpo.2021.103469

Selfridge M; Cunningham EB; Barnett T; Drost A; Gray-Schleihauf C; Guarasci K; Lundgren K; Milne R; Grebely J; Fraser C, 2021, 'Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada', International Journal of Drug Policy, 96, http://dx.doi.org/10.1016/j.drugpo.2021.103418

Matthews GV; Bhagani S; Van der Valk M; Rockstroh J; Feld JJ; Rauch A; Thurnheer C; Bruneau J; Kim A; Hellard M; Shaw D; Gane E; Nelson M; Ingiliz P; Applegate TL; Grebely J; Marks P; Martinello M; Petoumenos K; Dore GJ; Marks P; Feld J; Amjad S; Tu E; Tamaddoni M; Thurnheer MC; Gilleece Y; Fraser C; Moriggia A; Lutz T; Moon J; Read P; Kim AY; Ustianowski A; Cordes C; Sasadeusz J; Hull M; Braun D, 2021, 'Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection', Journal of Hepatology, 75, pp. 829 - 839, http://dx.doi.org/10.1016/j.jhep.2021.04.056

Santo T; Clark B; Hickman M; Grebely J; Campbell G; Sordo L; Chen A; Tran LT; Bharat C; Padmanathan P; Cousins G; Dupouy J; Kelty E; Muga R; Nosyk B; Min J; Pavarin R; Farrell M; Degenhardt L, 2021, 'Association of Opioid Agonist Treatment with All-Cause Mortality and Specific Causes of Death among People with Opioid Dependence: A Systematic Review and Meta-analysis', JAMA Psychiatry, 78, pp. 979 - 993, http://dx.doi.org/10.1001/jamapsychiatry.2021.0976

Kwon JA; Dore GJ; Hajarizadeh B; Alavi M; Valerio H; Grebely J; Guy R; Gray RT, 2021, 'Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications', PLoS ONE, 16, http://dx.doi.org/10.1371/journal.pone.0257369

Stephens J; Bradley C; Elliott S; Dore G; Grebely J; Alavi M; Kennedy B; Tong S; Ward J, 2021, 'Hepatitis C in South Australia and Northern Territory: a population-based linkage study', INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 50, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000695815900613&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Howe AYM; Ceccherini-Silberstein F; Dietz J; Popping S; Grebely J; Rodrigo C; Lennerstrand J; Douglas MW; Parczewsk M; Harrigan PR; Pawlotsky JM; Garcia F, 2021, 'SHARED: An international collaboration to unravel hepatitis C resistance', Viruses, 13, pp. 1580, http://dx.doi.org/10.3390/v13081580

Grebely J; Tran L; Degenhardt L; Dowell-Day A; Santo T; Larney S; Hickman M; Vickerman P; French C; Butler K; Gibbs D; Valerio H; Read P; Dore GJ; Hajarizadeh B, 2021, 'Association between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection among People Who Inject Drugs: A Systematic Review and Meta-analysis', Clinical Infectious Diseases, 73, pp. E107 - E118, http://dx.doi.org/10.1093/cid/ciaa612

Ferraro CF; Stewart DE; Grebely J; Tran LT; Zhou S; Puca C; Hajarizadeh B; Larney S; Santo T; Higgins JPT; Vickerman P; Degenhardt L; Hickman M; French CE, 2021, 'Association between opioid agonist therapy use and HIV testing uptake among people who have recently injected drugs: a systematic review and meta-analysis', Addiction, 116, pp. 1664 - 1676, http://dx.doi.org/10.1111/add.15316

Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ; Loveday S; Tamaddoni M; Obeid S; Estivill Mercade G; Martinez M; Donnelly R; Bowman J; Trevethan L; Lagios K; Murrell T; Bath N; Tawil V; Stevens A; Topp L; Churchill A; Pinnock K; Martin N; Drew S; Harrod M; Smith A; Williams R; Cooper B; Somes K; Burns C; Kaur A; Lobo C; Conroy K; McCredie L; Café C; Anlezark J; Rawlinson W; Yeang M; Wynn M; Willenborg C, 2021, 'Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study', The Lancet Gastroenterology and Hepatology, 6, pp. 533 - 546, http://dx.doi.org/10.1016/S2468-1253(21)00077-7

Valerio H; Alavi M; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Dore G; Grebely J, 2021, 'Progress towards Elimination of Hepatitis C Infection among People Who Inject Drugs in Australia: The ETHOS Engage Study', Clinical Infectious Diseases, 73, pp. E69 - E78, http://dx.doi.org/10.1093/cid/ciaa571

Nielsen S; Sanfilippo P; Belackova V; Day C; Silins E; Lintzeris N; Bruno R; Grebely J; Lancaster K; Ali R; Bell J; Dietze P; Degenhardt L; Farrell M; Larance B, 2021, 'Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities', Addiction, 116, pp. 1482 - 1494, http://dx.doi.org/10.1111/add.15297

Cunningham EB; Hajarizadeh B; Amin J; Hellard M; Bruneau J; Feld JJ; Cooper C; Powis J; Litwin AH; Marks P; Dalgard O; Conway B; Moriggia A; Stedman C; Read P; Bruggmann P; Lacombe K; Dunlop A; Applegate TL; Matthews GV; Fraser C; Dore GJ; Grebely J, 2021, 'Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection among People Who Inject Drugs', Clinical Infectious Diseases, 72, pp. 1392 - 1400, http://dx.doi.org/10.1093/cid/ciaa253

Back to profile page